0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
In This Issue of JAMA Neurology |

Highlights FREE

JAMA Neurol. 2014;71(12):1467. doi:10.1001/jamaneurol.2013.4181.
Text Size: A A A
Published online

RESEARCH

Liu and colleagues analyze purified neurons derived from human induced pluripotent stem cells from patients carrying 3 different presenilin 1 mutations and nondemented control individuals in the absence of any overexpression. Adult human skin biopsies were obtained from volunteers at the Alzheimer Disease Research Center, University of California, San Diego. The results suggest that biomarker signatures obtained with such models are misleading and that human neurons derived from human induced pluripotent stem cells provide a unique signature that will more accurately reflect drug response in human patients and in cerebrospinal fluid biomarker changes observed during γ-secretase modulator treatment. Editorial perspective is provided by Fan Liao, PhD, and David M. Holtzman, MD.

Gardner and coauthors quantify the risk of dementia among adults with recent traumatic brain injury (TBI) compared with adults with non-TBI trauma (NTT). All patients 55 years or older diagnosed as having TBI or NTT in 2005 and 2006 and who did not have baseline dementia or die during hospitalization (n = 164 661) were identified in a California statewide administrative health database of emergency department (ED) and inpatient visits. Among patients evaluated in the ED or inpatient settings, those with moderate to severe TBI at 55 years or older or mild TBI at 65 years or older had an increased risk of developing dementia. Editorial perspective is provided by Steven T. DeKosky, MD.

Langer-Gould and colleagues determine whether vaccines, particularly those for hepatitis B and human papillomavirus, increase the risk of multiple sclerosis (MS) or other central nervous system demyelinating syndromes (CNS ADS). A nested case-control study was conducted using data obtained from the complete electronic health records of Kaiser Permanente Southern California members. They found no longer-term association of vaccines with MS or any other CNS ADS, which argues against a causal association.

Russell and coauthors evaluate whether [18F]MNI-659 (2-(2-(3-(4-(2-[18F]fluoroethoxy)phenyl)-7-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-4-isopropoxyisoindoline-1,3-dione), a novel phosphodiesterase 10 positron emission tomography (PET) ligand, is a sensitive marker for striatal changes in early Huntington disease (HD). A cohort of individuals with HD, including premanifest (pre-HD) or manifest with motor signs (mHD), underwent clinical assessments, genetic determination, [18F]MNI-659 PET imaging, and brain magnetic resonance imaging. As a promising striatal imaging biomarker, [18F]MNI-659 is potentially capable of assessing the extent of disease in early mHD.

Kantarci et al investigate the effects of Alzheimer disease–related gray matter neurodegeneration and high β-amyloid on white matter microstructure in older adults without dementia. Participants included in the Mayo Clinic Study of Aging (N = 701) who underwent magnetic resonance imaging, diffusion tensor imaging (DTI), and positron emission tomography studies with diagnoses of cognitively normal (n = 570) or mild cognitive impairment (n = 131) were included. A high amyloid load does not influence DTI-based measures of white matter integrity in the absence of coexistent gray matter neurodegeneration in older adults without dementia.

Figures

Tables

References

Correspondence

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

1,685 Views
0 Citations
×

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs